Forsta AP Fonden decreased its position in Eli Lilly and Company (NYSE:LLY) by 11.8% during the second quarter, Holdings Channel reports. The firm owned 562,308 shares of the company’s stock after selling 75,500 shares during the period. Eli Lilly and accounts for approximately 1.3% of Forsta AP Fonden’s portfolio, making the stock its 17th largest position. Forsta AP Fonden’s holdings in Eli Lilly and were worth $46,278,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the company. First Command Financial Services Inc. boosted its stake in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the period. Heritage Trust Co bought a new stake in shares of Eli Lilly and during the first quarter worth $135,000. Point72 Asia Hong Kong Ltd boosted its stake in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock worth $148,000 after buying an additional 1,239 shares during the period. Penserra Capital Management LLC boosted its stake in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares during the period. Finally, American National Bank boosted its stake in shares of Eli Lilly and by 5.2% in the second quarter. American National Bank now owns 2,088 shares of the company’s stock worth $172,000 after buying an additional 104 shares during the period. Hedge funds and other institutional investors own 75.61% of the company’s stock.
Shares of Eli Lilly and Company (NYSE:LLY) traded down 0.47% on Friday, hitting $81.15. The stock had a trading volume of 2,446,392 shares. The firm has a market cap of $85.61 billion, a PE ratio of 35.11 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The firm’s 50-day moving average price is $82.91 and its 200 day moving average price is $81.72.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same period in the previous year, the business earned $0.86 EPS. The business’s quarterly revenue was up 7.8% on a year-over-year basis. On average, equities research analysts predict that Eli Lilly and Company will post $4.16 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.56%. The ex-dividend date is Friday, August 11th. Eli Lilly and’s payout ratio is currently 90.04%.
TRADEMARK VIOLATION NOTICE: “Forsta AP Fonden Has $46.28 Million Stake in Eli Lilly and Company (LLY)” was published by Stock Observer and is the property of of Stock Observer. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.thestockobserver.com/2017/08/12/forsta-ap-fonden-has-46-28-million-stake-in-eli-lilly-and-company-lly.html.
A number of brokerages recently weighed in on LLY. BidaskClub upgraded Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Barclays PLC upped their price objective on Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 4th. BMO Capital Markets restated a “sell” rating and set a $73.00 price objective on shares of Eli Lilly and in a research note on Friday, August 4th. Berenberg Bank restated a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a research note on Thursday, July 27th. Finally, Jefferies Group LLC restated a “buy” rating and set a $96.00 price objective (up from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating to the company. Eli Lilly and has an average rating of “Hold” and a consensus price target of $88.27.
In other Eli Lilly and news, insider Melissa S. Barnes sold 1,900 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the sale, the insider now directly owns 14,041 shares of the company’s stock, valued at approximately $1,134,231.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total value of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock valued at $55,845,287 over the last three months. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.